Alice H.
- Country
- Czechia
- Department
- #3166:Kardiologie
Research Overview
- Evaluation of Pelacarsen (TQJ230) in Reducing Major Cardiovascular Events in Patients with Established Cardiovascular Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
- Long-term Safety and Tolerability Evaluation of Pelacarsen in Patients with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease
Data & Insights
Has run more than one trial at 203 of 314 partner sites.
Specializations
Kardiologie
Clinical research activity in cardiology centered on atherosclerotic cardiovascular disease and broader cardiovascular disease, with interest in reducing major adverse cardiovascular outcomes in patients with established disease.
- Major adverse cardiovascular events
- Coronary revascularization
- Cardiovascular death
Work is linked to clinical evaluation of therapies targeting lipoprotein(a) in patients managed at Pro-Cardio s.r.o. in Liberec.
Lipoprotein(a)-targeted therapy
Investigator involvement includes therapeutic strategies focused on lowering lipoprotein(a) in the setting of established cardiovascular disease, reflecting interest in risk modification for high-risk patients.
- Lp(a) reduction
- Atherosclerotic risk
- Secondary prevention
The clinical focus is aligned with treatment approaches designed to address residual cardiovascular risk beyond standard care.
Secondary prevention in established cardiovascular disease
Research activity includes patients with prior cardiovascular events and ongoing disease burden, with emphasis on preventing recurrent ischemic outcomes in an ASCVD population.
- Non-fatal myocardial infarction
- Non-fatal stroke
- Urgent coronary revascularization
This area reflects a therapeutic interest in long-term event prevention among individuals with high cardiovascular risk.
Long-term safety and tolerability
Clinical involvement also covers extended assessment of treatment safety and tolerability for patients continuing therapy after prior participation in a cardiovascular study.
- Extended follow-up
- Treatment tolerability
- Chronic cardiovascular therapy
The therapeutic landscape includes continued monitoring of patients with elevated lipoprotein(a) and established cardiovascular disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.